POST-COVID-19 SYNDROME: SYMPTOMS AND RISK FACTORS
Relevance. Long COVID or post-COVID-19 syndrome first gained widespread recognition among social support groups and then in the scientific and medical community. The disease is poorly understood because it affects Covid-19 survivors at all levels of disease severity, even young adults, children and those who have not been hospitalized. The most common symptoms reported in many studies are radiation and shortness of breath, which continue for several months after acute COVID-19 illness.
Aim. Review of modern and relevant research on symptoms and risk factors for the development of post-Covid syndrome.
Search strategy. A systematic search was conducted without language restrictions from database inception in PubMed/MEDLINE, The Cochrane Library, Web of Science Core Collection, Google/Google Scholar and selected reference lists. Primary research articles were selected that assessed people at least 12 weeks after a confirmed diagnosis of COVID-19 and specifically reported on fatigue, cognitive impairment, inflammatory parameters, or functional impairment outcomes. A number of original articles and reviews on research topics over the past 5 years have been analyzed, this is the period 2019-2024. The main words were used: complication of acute COVID-19, post-Covid syndrome after acute COVID-19, prolonged COVID-19, chronic COVID-19. The literature search yielded 2786 studies, of which 89 studies were selected for inclusion.
Results. Post-COVID-19 syndrome is defined by the persistence of clinical signs and symptoms that occur during or after exposure to COVID-19, persist for more than 12 weeks, and are not explained by an alternative diagnosis. Symptoms may fluctuate or flare up. It is a heterogeneous disease that includes post-viral chronic fatigue syndrome, multi-organ damage and the consequences of severe hospitalization after intensive care. 10–65% of survivors of mild or moderate COVID-19 experience symptoms of post-coronavirus syndrome for 12 weeks or more. After six months, patients report an average of 14 persistent symptoms. The most common symptoms are fatigue, shortness of breath, disturbances in attention, concentration, memory and sleep, anxiety and depression. The underlying biological mechanisms are unknown, although abnormal or excessive autoimmune and inflammatory responses may play an important role.
Conclusions. The global pandemic of Covid-19 infection has led to the emergence of the chronic disease Covid-19, which reduces the quality of life of patients and leads to multiple organ damage. Long-term Covid infection has become an important problem attracting the attention of science and medical scientists. Even if we assume that only 10 percent of those infected with Covid develop long Covid, this means that around 5 million people worldwide suffer from long Covid. But this figure could be even higher. The information presented in this review, which is not widely available elsewhere in the literature, may serve as a starting point for further research into long COVID.
Altay А. Dyussupov1, https://orcid.org/0000-0003-0875-1020
Zhanar M. Zhumanbayeva 1, https://orcid.org/0000-0001-8941-862Х
Ynkar O. Kairkhanova1, https://orcid.org/0000-0001-9533-1723
Аltynai М. Dosbayeva1, https://orcid.org/0000-0002-0554-2680
Ainur S. Кrykpaeva1 http://orcid.org/0000-0001-7701-9832
Askar S. Serikbayev1, https://orcid.org/0000-0002-6077-5065
Kuralai Sh. Amrenova1, http://orcid.org/0000-0001-7701-9832
Asanali A. Seitkabylov1, Rinat N. Kudaibergenov1
1. Абдурахимов А.Х., Хегай Л.Н., Юсупова Ш.К. COVID-19 и его осложнения. Re-health journal, 2021, 4 (12), С. 61-74.
2. Асфандиярова Н.С. Постковидный синдром. Клиническая медицина. 2021. 99(7–8):429–435. DOI: http://dx.doi.org/10.30629/0023-2149-2021-99-7-8-429-435
3. Ахметова А.К., Еркинкызы Д. COVID-19 в Казахстане: эпидемиология и клиника. Вестник науки, 2021, vol. 3, no. 4 (37), С. 106-111.
4. Белоцерковская Ю.Г., Романовских А.Г., Смирнов И.П., Синопальников А.И. Долгий COVID-19. Consilium Medicum. 2021. 23 (3): 261–268. DOI: 10.26442/20751753.2021.3.200805
5. Вера Н.Л., Головко М. Г., Ларин В.Г. Влияние коронавирусной инфекции (COVID-19) на сердечно-сосудистую систему. Вестник Российского государственного медицинского университета, 2020, 2, pp. 5-13. doi:10.24075/vrgmu.2020.020
6. Всемирная организация здравоохранения. За два года пандемии от COVID-19 или его последствий умерли почти 15 млн человек (2022). https://www.fontanka.ru/2022/05/05/71309837/.
7. Всемирная организация здравоохранения отменила режим чрезвычайной ситуации в мире из-за COVID-19. Forbes.ru (5 мая 2023).
8. Всемирная организация здравоохранения. Вступительное слово Генерального директора на пресс брифинге по COVID-19 11 марта 2020 г. (11 марта 2020).
9. Всемирная организация здравоохранения. Заявление по итогам второго совещания Комитета по чрезвычайной ситуации в соответствии с Международными медико-санитарными правилами, в связи со вспышкой заболевания, вызванного новым коронавирусом 2019 г. (nCoV). (30 января 2020).
10. Маукаева С.Б., Токаева А.З., Исабекова Ж.Б., Смаил Е.М., Нуралинова Г.И., Тренина В.А., Каримова С.С., Киебаева А.Ж., Битимиров С.Н., Жунусов Е.Т. "COVID-19 в Казахстане и Восточно-Казахстанской области. Наука и здравоохранение, 2020, 22(3), С.12-16.
11. Медицинская реабилитация детей, перенесших COVID19 в режиме дистанционного дневного стационара с использованием цифровых технологий. Временное методическое руководство № 71 (PDF). Департамент здравоохранения города Москвы (2020).
12. Наименование заболевания, вызванного коронавирусом (COVID-19), и вирусного возбудителя. https://www.who.int/ru/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it
13. Amsalem D., Dixon L.B., Neria Y. The coronavirus disease 2019 (COVID-19) outbreak and mental health: current risks and recommended actions. JAMA Psychiatry 2021; 78: 9-10.
14. Arnold D.T., Hamilton F.W., Milne A., Morley A.J., Viner J., Attwood M., et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. 2021;76(4):399–401.
15. Bahmer T., Borzikowsky C., Lieb W., Horn A., Krist L, Fricke J., et al. Severity, predictors and clinical correlates of post-COVID syndrome (PCS) in Germany: a prospective, multi-centre, population-based cohort study. E Clinical Medicine. 2022;51:101549
16. Balbi M, Conti C, Imeri G, Caroli A, Surace A, Corsi A, Mercanzin E, et al. Post-discharge chest CT findings and pulmonary function tests in severe COVID-19 patients. Eur J Radiol 138: 109676, 2021.
17. Buonsenso D., Espuny Pujol F., Munblit D., et al. Clinical characteristics, activity levels and mental health problems in children with Long COVID: a survey of 510 children. Preprints. 2021. DOI: 10.20944/preprints202103.0271.v1
18. Buonsenso D., Munblit D., De Rose C., et al. Preliminary Evidence on Long Covid in children. Acta Paediatr. 2021. DOI: 10.1111/apa.15870
19. Callard F., Perego E. How and why patients made Long Covid. Social Science & Medicine. 2021;268:113426.
20. Cares-Marambio K., Montenegro-Jiménez Y., Torres-Castro R., et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. Chron Respir Dis. 2021;18:14799731211002240.
21. Carfì A., Bernabei R., Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 324: 603–605, 2020.
22. Carfi A., et al. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605.
23. Carfi A., Bernabei R., Landi F. Gemelli Against C-P-ACSG Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605.
24. Carod-Artal F.J. Neurological complications due to coronavirus and COVID-19. Rev Neurol 2020; 70: 311-22.
25. Carvalho-Schneider C., Laurent E., Lemaignen A., Bourbao-Tournois E., Lemaignen C., Laribi S., et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. 2021. 27(2):258–263.
26. CDC. Post-COVID conditions: information for healthcare providers. 2022. https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html Accessed.
27. Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020. Vol. 395, iss. 10223. P. 497—506. ISSN 0140-6736. doi:10.1016/S0140-6736(20)30183-5.
28. Chopra V., Flanders S.A., O'Malley M., Malani A.N., Prescott H.C. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med 174: 576–578, 2021.
29. Coronavirus disease (COVID-19) Pandemic. Geneva: World Health Organization, May 2, 2021. URL: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Last consultation date: 05/04/2021.
30. COVID-19 rapid guideline: managing the long-term effects of COVID-19. 2021. https://www.nice.org.uk/guidance/ng188 Accessed 16th, November, 2022.
31. Dani M., Dirksen A., Taraborrelli P., et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med. 2021;21(1):e63–e67.
32. David Adam. 15 million people have died in the pandemic, WHO says. The World Health Organization’s long-awaited estimate of excess COVID deaths is in line with other studies. Nature (5 мая 2022). doi:10.1038/d41586-022-01245-6.
33. Del Rio C., Collins LF, Malani P. Long-term Health Consequences of COVID. JAMA. 2020;324(17):1723.
34. Dennis A., Wamil M., Alberts J., et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ Open. 2021;11(3):e048391.
35. Desai A.D., Lavelle M., Boursiquot B.C., Wan E.Y. Long-term complications of COVID-19. Am J Physiol Cell Physiol. 2022 Jan 1;322(1):C1-C11.
36. Dweck M.R., Bularga A., Hahn R.T., Bing R., Lee K.K., Chapman A.R., et al. Global evaluation of echocardiography in patients with COVID-19. Eur Heart J Cardiovasc Imaging 21: 949–958, 2020.
37. Garrigues E., Janvier P., Kherabi Y., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020. 81(6):e4–e6.
38. Gregory A. Covid-19 is no longer a global health emergency, says WHO. The Guardian. 2023. 05.05.
39. Girard T.D., Jackson J.C., Pandharipande P.P. et al. Delirium as a predictor of long-term cognitive impairment in survivors of critical illness. Crit Care Med. 2010. 38(7):1513–1520.
40. Gross A.L., Jones RN, Habtemariam DA, et al.. Delirium and long-term cognitive trajectory among persons with dementia. Arch Intern Med. 2012. 172(17):1324–1331.
41. Halpin S.J., Mclvor C., Whyatt G., et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation. J Med Virol. 2021. 93(2):1013–1022.
42. Hastie C.E., Lowe D.J., McAuley A., Winter A.J., Mills N.L., Black C., et al. Outcomes among confirmed cases and a matched comparison group in the Long-COVID in Scotland study. Nat Commun. 2022. 13(1):5663.
43. Hendren N.S., Drazner M.H., Bozkurt B., Cooper L.T. Description and proposed management of the acute COVID-19 cardiovascular syndrome. Circulation 141: 1903–1914, 2020.
44. Huang C., Huang L., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. 2021. 397(10270):220–232.
45. Kang Y., Chen T., Mui D., Ferrari V., Jagasia D., Scherrer-Crosbie M., Chen Y., Han Y. Cardiovascular manifestations and treatment considerations in COVID-19. Heart 106: 1132–1141, 2020.
46. Kim Y., Kim S.E., Kim T., Yun K.W., Lee S.H., Lee E., et al. Preliminary guidelines for the clinical evaluation and management of long COVID. Infect Chemother. 2022.54(3):566–597.
47. Ladds E., Rushforth A., Wieringa S., Taylor S., Rayner C., Husain L., et al. Persistent symptoms after COVID-19: qualitative study of 114 'long COVID' patients and draft quality principles for services. BMC Health Serv Res 2020. 20: 1144.
48. Li A.Y., Li W.X., Li J. Emerging trends in management of long COVID with a focus on pulmonary rehabilitation: A review. Clin Respir J. 2024.18(5):e13777
49. Lu Y., Li X., Geng D, et al. Cerebral micro-structural changes in COVID-19 patients – An MRI-based 3-month follow-up study. E Clinical Medicine. 2020. 25:100484.
50. Ludvigsson J.F. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID. Acta Paediatr. 2021;110(3):914–921.
51. Mandal S., Barnett J., Brill S.E., et al. ARC Study Group. 'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax 76: 396–398, 2021.
52. McDonald L.T. Healing after COVID-19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol 320: L257–L265, 2021.
53. McMahon D.E., Gallman A.E., Hruza G.J. et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. The Lancet Infectious Diseases. 2021. 21(3):313–314.
54. Mitrani RD, Dabas N, Goldberger JJ.. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm. 2020;17(11):1984–1990.
55. Miyazato Y., Morioka S., Tsuzuki S., et al. Prolonged and late-onset symptoms of coronavirus disease 2019. Open Forum Infect Dis. 2020.7(11):ofaa507.
56. Moody W.E., Liu B., Mahmoud-Elsayed H.M., et al. Persisting Adverse Ventricular Remodeling in COVID-19 Survivors: A Longitudinal Echocardiographic Study. Journal of the American Society of Echocardiography. 2021. 34(5):562–566.
57. Moreno-Perez O., Merino E., Leon-Ramirez J.M., Andres M., Ramos J.M., Arenas-Jimenez J., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: a Mediterranean cohort study. J Infect. 2021;82(3):378–383.
58. Nalbandian A., Sehgal K., Gupta A., Madhavan M.V, McGroder C., Stevens J.S., et al. Post-acute COVID-19 syndrome. Nat Med. 2021. 27(4):601–615.
59. Number of COVID-19 deaths reported to WHO (cumulative total). data.who.int/covid19/deaths
60. Office for National Statistics (ONS). The prevalence of long COVID symptoms and COVID-19 complications. URL:https://www.ons.gov.uk/news/statementsandletters/theprevalenceoflongcovidsymptomsandcovid19complications. Last consultation date: 04/30/2021.
61. Paterson R.W., Brown R.L., Benjamin L. et al. The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. Brain. 2020. 143(10):3104–3120.
62. Poorolajal J. The global pandemics are getting more frequent and severe. Journal of Research in Health Sciences. 2021. Vol.21, no.1. P. e00502. doi:10.34172/jrhs.2021.40. PMID 34024760.
63. Poyraz BC, Poyraz CA, Qlgun Y, et al.. Psychiatric morbidity and protracted symptoms after COVID-19. Psychiatry Res. 2020. 295:113604
64. Puntmann V.O., Carerj M.L., Wieters I., et al. Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020. 5(11):1265–1273.
65. Rajpal S., Tong M.S., Borchers J., et al. Cardiovascular magnetic resonance findings in competitive athletes recovering from COVID-19 infection. JAMA Cardiol. 2020. 6(1):116–118.
66. Raman B., Cassar M.P., Tunnicliffe E.M., et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. E Clinical Medicine. 2021. 31:100683.
67. Richter D., Guasti L., Koehler F., Squizzato A., Nistri S., et al. Late phase of COVID-19 pandemic in general cardiology. A position paper of the ESC Council for Cardiology Practice. ESC Heart Fail 8: 3483–3494, 2021.
68. Rogers J.P., Chesney E., Oliver D., et al. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry. 2020.7(7):611–627.
69. Shah W., Hillman T., Playford E.D. et al. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021. 372:n136.
70. Sigfrid L., Drake T.M., Pauley E. et al. Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol. medRxiv. 2021. DOI:10.1101
71. Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. Condition WHOCCDWGoP-C-. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022. 22(4):e102–e107.
72. Stavem K., Ghanima W., Olsen M.K., et al. 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax. 2021. 76(4):405.
73. Statement on the fifteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic (англ.). www.who.int (5.05.2023). — «The WHO Director-General concurs with the advice offered by the Committee regarding the ongoing COVID-19 pandemic. He determines that COVID-19 is now an established and ongoing health issue which no longer constitutes a public health emergency of international concern (PHEIC)».
74. Subramanian A., Nirantharakumar K., Hughes S., Myles P., Williams T., Gokhale K.M., et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med. 2022. 28(8):1706–1714.
75. Sudre C.H., Murray B., Varsavsky T., et al. Attributes and predictors of long COVID. Nat Med. 2021. 27(4):626–631.
76. Tabacof L., Tosto-Mancuso J., Wood J., Cortes M., Kontorovich A., McCarthy D., et al. Post-acute COVID-19 syndrome negatively impacts physical function, cognitive function, health-related quality of life, and participation. Am J Phys Med Rehabil. 2022. 101(1):48–52.
77. Taquet M., Geddes J.R., Husain M. et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records'. The Lancet Psychiatry. 2021. 8(5):416–427.
78. Taquet M., Luciano S., Geddes J.R., Harrison P.J. Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry 8: 130–140, 2021.
79. Tomasoni D., Bai F., Castoldi R., Barbanotti D., Falcinella C., Mulè G., et al. Anxiety and depression symptoms after virological clearance of COVID-19: a cross-sectional study in Milan, Italy. J Med Virol 2021. 93: 1175-9.
80. Townsend L., Dowds J., O'Brien K., et al. Persistent poor health post-COVID-19 is not associated with respiratory complications or initial disease severity. Ann Am Thorac Soc. 2021. DOI: 10.1513/AnnalsATS.202009-1175OC
81. Townsend L., Dyer A.H., Jones K., et al. Persistent fatigue following SARS-CoV-2 infection is common and independent of severity of initial infection. PLoS One. 2020.15(11):e0240784.
82. Van den Borst B, et al.. Comprehensive health assessment three months after recovery from acute COVID-19. Clin Infect Dis. 2020;ciaa1750.
83. Wichmann D. Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med 173: 1030, 2020.
84. Wong A.W., Shah A.S., Johnston J.C. et al. Patient-reported outcome measures after COVID-19: a prospective cohort study. Eur Respir J. 2020. 56(5):2003276.
85. Woo M.S., Malsy J., Pottgen J. et al. Frequent neurocognitive deficits after recovery from mild COVID-19. Brain Commun. 2020.2(2):fcaa205.
86. «World Health Organization» Coronavirus (COVID-19) Dashboard. data.who.int/covid19/cases Всемирная организация здравоохранения.
87. Xiong Q., Xu M., Li J., et al. Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study'. Clin Microbiol Infect. 2021.27(1):89–95.
88. Yong S.J. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021 Oct.53(10):737-754. doi: 10.1080/23744235.2021.1924397. Epub 2021 May 22. PMID: 34024217. PMCID: PMC8146298.
89. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020. 382: 727-33.
Number of Views: 233
Bibliography link
Dyussupov A.А., Zhumanbayeva Zh.M., Kairkhanova Y.O., Dosbayeva А.М., Кrykpaeva A.S., Serikbayev A.S., Amrenova K.Sh., Seitkabylov A.A., Kudaibergenov R.N. Post-COVID-19 syndrome: symptoms and risk factors // Nauka i Zdravookhranenie [Science & Healthcare]. 2024. Vol.26 (5), pp. 129-140. doi 10.34689/SH.2024.26.5.017Related publications:
COMMUNITY-ACQUIRED PNEUMONIA IN PREGNANT. CLINICAL CASE.
THE RELATIONSHIP BETWEEN BODY MASS INDEX AND BONE MINERAL DENSITY IN THE MIDDLE-AGED AND ELDERLY POPULATION
CURRENT STATE OF DERMATOPHYTE RESISTANCE TO ANTIMYCOTIC AGENTS
CLINICAL, MORPHOLOGICAL AND MORPHOMETRIC ASSESSMENT OF GRANULOMATOUS INFLAMMATION IN SARCOIDOSIS AND PULMONARY TUBERCULOSIS
DRUG-INDUCED LIVER INJURY IN HIV-INFECTED PATIENTS WITH ACTIVE TUBERCULOSIS: COMPARATIVE LABORATORY CHARACTERIZATION